

CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this New Application Transmittal and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date July 12, 2001 in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number ET059018474US addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Eva Cavalli
(Print Name)

Landaulle
(Signature)

ASSISTANT COMMISSIONER FOR PATENTS BOX PATENT APPLICATION Washington, D.C. 20231

Roche Molecular Systems, Inc. 1145 Atlantic Ave.

Alameda, CA 94501 Docket No.: RPA1003

July 12, 2001

Sir:

Transmitted herewith for filing under 37 C.F.R. § 1.53(b) is the patent application of

Inventor(s): Ann Begovich, Henry Erlich, Andrew Grupe, Janelle Noble, Gary Peltz, Karen Walker, Rebecca Reynolds and Gabriele Zangenberg

For: TCF-1 NUCLEOTIDE SEQUENCE VARIATION

l.	Encl	losed	are:	
----	------	-------	------	--

[x] 65 pages of specification		
[] sheet(s) of drawing. [] formal [] informal		
[x]5page(s) of Declaration and Power of Attorney [] Newly executed [] Copy from a prior application		
[x]5page(s) of Sequence Listing		
[x]1_ computer disk(s) containing Sequence Listing		
[x] Statement under 37 CFR § 1.821 or 37 C.F.R. § 1.825		
[] Preliminary Amendment		
[] Revocation and Power of Attorney		

	2. Pri		35 U.S.C. § 119			
	•		gn Priority			
		[]	Foreign Priority of application(s) number is claimed under 35 U.S.C. § 119(a)-(d)			
		[] No	The certified copy(ies) has(have) been filed in pri on	or U.S. patent application Serial		
		[]	The certified copy(ies) will follow.			
		Priori	ity To Provisional Application(S) Under 35 U.S.C. §	§ 119(e)		
			riority of prior provisional application Serial Noe c) claimed under 35 U.S.C. § 119(e).	60/219,812 filed on 7/21/00		
wer trust that		[] Amend the specification by inserting, before the first line, the following sentence: This application claims priority under 35 U.S.C. § 119(e) of provisional application Serial No, filed				
# DUM: 21 B	3. Re	elation back under 35 U.S.C. § 120				
0 10 mins			he present application is a [] continuation [] divisional [] continuation-in-part (CIP) for application Serial No, filed			
		[]Ar This a	mend the specification by inserting, before the first application claims priority under 35 U.S.C. § 120 of filed	line, the following sentence:		
		[]A	copy of the oath or declaration from a prior applica	tion noted above is enclosed.		
		declar	he entire disclosure of the prior application, from what wation is supplied is considered as being part of the cation and is hereby incorporated by reference there	disclosure of the accompanying		
		[] Po	ower of attorney: [] The power appears in the original papers of the signal papers of the prior application is enclosed. [] Recognize as associate attorney			

- [] Cancel in this application original claims _____ of the prior application before calculating the filing fee (At least one original independent claim must be retained for filing purposes).
- 4. The fee has been calculated as shown below:

CLAIMS (as amended	l in §3, if applicable	e)		
FOR	NO. FILED	NO. EXTRA	RATE	FEE
TOTAL CLAIMS	17	0	x \$18	0
INDEP. CLAIMS	7	4	x \$80	\$320
MULTIPLE DEPENDENT CLAIMS PRESENTED + \$270 0				
BASIC FEE \$710				
TOTAL <u>\$ 1,030.00</u>				

- 5. [X] Please charge my Deposit Account No. 500812 in the amount of \$1,030.00. This sheet is provided in duplicate.
- 6. [X] The Commissioner is hereby authorized to charge payment of the following fees or any additional fees associated with this communication or credit any overpayment to Deposit Account No. 500812. This sheet is provided in duplicate.
 - [X] Any filing fees required under 37 C.F.R. § 1.16.
 - [X] Any patent application processing fees under 37 C.F.R. § 1.17.
- 7. [X] Address all communications to: Customer No. 22829

Douglas A. Petry, Ph.D.

Reg. No. 35,321

Agent for Applicant(s)

Customer No. 22829

(510) 814-2874 Telephone

(510) 814-2977 Telefax

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application	
Inventor's Name(s): Begovich et al. Serial No. Filed: Concurrent herewith	Group: Examiner:
For: TCF-1 NUCLEOTIDE SEQUENC	TE VARIATION
	CATEMENT CFR §1.821 or §1.825
Assistant Commissioner for Patents Washingotn, D.C. 20231	Alameda, CA 94501 July 12, 2001
Sir:	
I hereby certify that:	
x The contents of the paper Sec	quence Listing and computer readable Sequence Listing
submitted herewith are the sar	me. (37 CFR §1.821(f))
The contents of the paper Sequence Listing and computer readable Sequence Listing	
submitted herewith are the sa	nme. No new matter is included. (37 CFR §1.821(f) &
(g))	

Each of the substituted sheets of the paper	er Sequence Listing submitted herewith is
supported in the captioned application.	No new matter is included. (37 CFR
§1.825(a))	

The contents of the substitute paper Sequence Listing and substitute computer readable Sequence Listing submitted herewith are the same. No new matter is included. (37 CFR §1.825(a) & (b))

The substitute computer readable Sequence Listing submitted herewith is identical to that originally filed. (37 CFR §1.825(d))

Respectfully submitted,

Douglas A. Petry, Ph.D.

Agent for Applicant(s)

Reg. No. 35,321

1145 Atlantic Avenue

Alameda, CA 94501

(510) 814-2874 Telephone

(510) 814-2973 Telefax